Business Context and Reporting Period
Company: MEDICINOVA INC
Filing Type: Form 8-K (Current Report)
Date of Report: July 8, 2014
Reporting Period: Events occurring on July 8, 2014, and July 9, 2014.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation agreements.
Material Changes
Entry into Material Definitive Agreement (Item 1.01)
On July 8, 2014, the Board approved, and on July 9, 2014, the Company entered into new Severance Protection Agreements with four executive officers: Yuichi Iwaki (CEO), Masatsune Okajima (VP), Kazuko Matsuda (CMO), and Geoffrey O'Brien (VP).
- Trigger Event: Termination of employment within 12 months following a "Change in Control" (defined as acquisition of 40%+ voting securities, change in majority of Board, merger resulting in 50%+ ownership change, or liquidation).
- Benefits upon Qualifying Termination:
- Accrued compensation and pro rata bonus (lump sum within 5 days).
- Cash payment equal to two times the sum of base salary and bonus amount, plus estimated premium costs for life and disability benefits over 18 months (payable on the 60th day following termination upon execution of a release).
- COBRA medical, dental, and vision coverage for 18 months.
- Outplacement services for up to 12 months.
- Full acceleration of vesting for unvested equity-based compensation awards.
- Term: Agreements expire December 31, 2014, with automatic one-year renewals unless notice of non-renewal is provided by October 1.
Reconstitution of Board Committees (Item 8.01)
On July 8, 2014, the Board reconstituted its committees as follows:
| Committee | Members | Chair |
|---|---|---|
| Audit Committee | Jeff Himawan, Yoshio Ishizaka, Yutaka Kobayashi, Hiroaki Shigeta | Yoshio Ishizaka |
| Compensation Committee | Jeff Himawan, Yoshio Ishizaka, Yutaka Kobayashi, Hiroaki Shigeta | Hiroaki Shigeta |
| Nominating and Corporate Governance Committee | Yoshi Ishizaka, Yutaka Kobayashi, Hiroaki Shigeta | Yutaka Kobayashi |
Guidance, Outlook, and Risks
Management Commentary: The filing states that payments under the agreements will comply with Internal Revenue Code Section 409A. If an excise tax would be imposed, payments will be reduced to the extent necessary to avoid such tax.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies beyond the financial obligations triggered by a potential Change in Control.
Investor Verification Checklist
- Verify the specific "base salary" and "bonus amount" figures for the named executives to calculate potential severance liabilities.
- Review the full text of the Severance Protection Agreement (Exhibit 10.1) for detailed definitions of "cause," "good reason," and "Change in Control."
- Confirm the current status of the Board of Directors to ensure the committee compositions listed are accurate as of the filing date.
- Assess the impact of the automatic renewal clause on future compensation obligations if no Change in Control occurs.